ClinicalTrials.gg
CompletedNCT00645268Updated Feb 1, 2021

A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes

A Phase 4 interventional study of sildenafil and placebo in Erectile Dysfunction and Diabetes Mellitus, Type 2, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 29 sites in 2 countries. Open to male participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
35 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.

Planned enrollment
10th of 50
300 · median 108
Started
2002
with 2 others
Phase 4
30 of 50
none open now
Registered
24th of 50
by date
Lead sponsor
23 of 50
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 10th largest by planned enrollment, is one of 3 that started in 2002, is one of 30 in phase 4, and was the 24th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 35 Years to 70 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing sildenafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

To determine the effect on erectile function in a population of type 2 diabetic men with erectile dysfunction who have undergone the following treatment regimen: pre-treatment with a daily dose of double-blind sildenafil versus placebo for 4 weeks (Phase I) followed by an as-needed, flexible-dose, open-label treatment phase with sildenafil for 12 weeks (Phase II). To assess safety and tolerability of this dosing regimen and to investigate its effects on endothelial function and subject's responses to the Self-Esteem And Relationship (SEAR) questionnaire.

03

Conditions studied

  • Erectile Dysfunction
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients had a documented clinical diagnosis of erectile dysfunction, a sexual partner for the duration of the study, and have a HbAlc of less than or equal to 10 at screening. Type 2 diabetic patients currently on insulin or on combination therapy with an oral hypoglycemic agent were not excluded.

Exclusion criteria

Exclusion Criteria:

Excluded were subjects who had taken more than 6 doses of any PDE5 inhibitor and/or had taken their last dose less than 4 weeks prior to the screening visit; subjects with resting sitting and/or standing hypotension (BP \< 90/50mmHg) or hypertension (BP > 170/110mmHg); and subjects with significant cardiovascular disease, including cardiac failure, myocardial infarction, unstable angina, stroke or (TIA), symptomatic or cardiac arrhythmias including atrial fibrillation in the last 3 months.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Arm 1

    Drug: sildenafil

  • Placebo comparator
    Arm 2

    Drug: placebo

  • Other
    Open-Label Arm

    Drug: sildenafil

Interventions

  • In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.

  • Drugplacebo

    In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.

  • Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).

06

What researchers measure

Primary outcomes

  1. The IIEF Erectile Function (EF) Domain score

    Time frame: Week 4

Secondary outcomes

  1. Intercourse success rate based on Event Logs

    Time frame: continuous

  2. Ability to obtain an erection hard enough to attempt sexual intercourse post dose of sildenafil

    Time frame: continuous

  3. Responses to the Self-Esteem And Relationship (SEAR) Questionnaire (including individual domain scores for the Sexual Activity, Self-Esteem And Relationship domains)

    Time frame: Week 16

  4. Responses to International Index of Erectile Function (IIEF) and secondary IIEF Domain scores (Orgasm; Desire; Intercourse Satisfaction; Overall Satisfaction)

    Time frame: Week 16

  5. Reponses to the Global Efficacy Assessment Questions

    Time frame: Week 16

  6. Flow mediated brachial artery dilation (FMD) as an index of generalized endothelial function

    Time frame: Week 4, 6, and 16

07

Study locations

29 sites
  • Pfizer Investigational Site
    Huntsville, Alabama 35801, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85006, United States
  • Pfizer Investigational Site
    Beverly Hills, California 90212, United States
  • Pfizer Investigational Site
    Duarte, California 91010, United States
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    La Jolla, California 92093, United States
  • Pfizer Investigational Site
    Laguna Woods, California 92653, United States
  • Pfizer Investigational Site
    Los Angeles, California 90048, United States
  • Pfizer Investigational Site
    San Diego, California 92161, United States
  • Pfizer Investigational Site
    Norwalk, Connecticut 06850, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06708, United States
  • Pfizer Investigational Site
    New Albany, Indiana 47150, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66211, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70112, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21224, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21287, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02215, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55416, United States
  • Pfizer Investigational Site
    Richmond Heights, Missouri 63117, United States
  • Pfizer Investigational Site
    Saint Louis, Missouri 63104, United States
  • Pfizer Investigational Site
    Buffalo, New York 14209, United States
  • Pfizer Investigational Site
    Medford, Oregon 97504, United States
  • Pfizer Investigational Site
    Portland, Oregon 97201, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78217, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229-3894, United States
  • Pfizer Investigational Site
    Kirkland, Washington 98034, United States
  • Pfizer Investigational Site
    Tacoma, Washington 98023, United States
  • Pfizer Investigational Site
    Tacoma, Washington 98405, United States
  • Pfizer Investigational Site
    Calgary, T2N2T9, Canada
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002 and a completion of Jan 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2008
First posted
Mar 27, 2008
Start
Dec 2002
CompletionActual
Jan 2004
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00645268
Responsible party
Sponsor
First posted
Mar 27, 2008
Start date
Dec 2002
Completion
Jan 2004
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion